Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
The primary tumors and metastases from 30 patients with stage II breast carcinoma treated with low- or standard-dose combination chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil) were studied by the immunoperoxidase technique for pregnancy-associated plasma protein A (PAPP-A), pregnancy-specific beta-1-glycoprotein (SP-1), and placental protein five (PP-5). In addition to immunostaining, 25 traditional clinicopathologic features were assessed with respect to early (at less than two years) recurrence. Of the 11 patients with early recurrences, nine (82 per cent) were PAPP-A-positive, while 16 of the 19 patients without early recurrences (84 per cent) were PAPP-A-negative (P less than 0.0005). None of the other clinicopathologic features correlated with early recurrence. Immunostaining for PAPP-A is thus a clinically significant predictor of early recurrence in patients with stage II breast carcinoma.
Kuhajda
F P
FP
Abeloff
M D
MD
Eggleston
J C
JC
D000328:Adult; D001943:Breast Neoplasms / Q000175:diagnosis / Q000473:pathology*; D005260:Female; D006023:Glycoproteins; D006801:Humans; D007158:Immunologic Techniques; D008875:Middle Aged; D009367:Neoplasm Staging; D011257:Pregnancy Proteins / Q000032:analysis* / Q000276:immunology; D011268:Pregnancy-Specific beta 1-Glycoproteins / Q000032:analysis / Q000276:immunology; D012008:Recurrence; D013194:Staining and Labeling; D013997:Time Factors
D006023:Glycoproteins; D011257:Pregnancy Proteins; D011268:Pregnancy-Specific beta 1-Glycoproteins; C021240:tissue-factor-pathway inhibitor 2